Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03230175
Other study ID # TTCRNE-1501
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 4, 2017
Est. completion date April 1, 2019

Study information

Verified date May 2021
Source Tissue Tech Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is hypothesized that application of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer will, with concomitant management of infection, result in a higher proportion of wounds showing complete healing within 16 weeks of initiating therapy.


Description:

The hypothesis under study is that one or more applications of TTAX01 to the wound surface of a well debrided, complex diabetic foot ulcer managed with appropriate antibiotic therapy will result in a higher probability of complete healing than would be expected from management with standard care alone. In this open label Phase 2 pilot trial, all subjects will receive the intervention over a maximum period of 16 weeks. Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary. Consenting subjects who qualify for enrollment will undergo an aggressive surgical debridement at the baseline visit, including biopsies of bone for histology and microbiologic testing at the start and completion of debridement. Systemic antibiotics will be given empirically, with adjustments made on the basis of culture and sensitivity results. New or recurrent infections will be managed with additional debridement and adjustment or addition of appropriate systemic antibiotics. The test article, TTAX01, will be sutured to the debrided wound bed at baseline and again at 4 week intervals over the 16 week treatment period for wounds that do not show evidence of healing. For wounds that do show evidence of healing, additional applications of TTAX01 will be withheld, based on observations from retrospective case series. Subjects whose wounds close prior to 16 weeks will move directly to a 2 week confirmation of closure period. Subjects whose wounds have not closed by the end of 16 weeks will exit the trial.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date April 1, 2019
Est. primary completion date January 10, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The subject has signed the informed consent form - The subject is male or female, at least 18 years of age inclusive at the date of Screening - The subject has confirmed diagnosis of Type I or Type II diabetes - The subject's index ulcer is located on the plantar surface, inter digital, heel, or lateral or medial surface of the foot - The subject has an index ulcer with visible margins having an area =1.0 cm2 to = 10.0 cm2 when measured by the electronic measuring device at Screening - The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule - The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (x-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis - The subject has an Ankle Brachial Index = 0.7 to = 1.3 or TcPO2 = 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure = 50 mmHg - The subject is under the care of a physician for the management of Diabetes Mellitus Exclusion Criteria: - The subject's index ulcer is primarily located on the dorsal surface of the foot - The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure - The subject has a glycated hemoglobin A1c (HbA1c) level of > 12% - The subject has a serum albumin level = 2.0 g/dL - The subject has a white blood cell count < 2.0 x109/L, neutrophils < 1.0 x109/L, or platelets < 100 x109/L - The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening - The subject is pregnant - The subject is a nursing mother - The subject's index ulcer is over an active Charcot deformity - The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer - Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis

Study Design


Intervention

Biological:
TTAX01
TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
Procedure:
Surgical resection and debridement
Perform surgical sharp debridement in the OR, to remove: infectious agents and biofilms (purulence), all debris, eschar, callus and macerated non-viable tissue from the wound base, and dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge. Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate.
Drug:
Systemic antibiotics
Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
Device:
Off-loading
Provide off-loading device appropriate to the location of wound with full length boot or total contact cast

Locations

Country Name City State
United States University of North Carolina Chapel Hill North Carolina
United States Futuro Clinical Trials, LLC McAllen Texas
United States University of Miami Miami Florida
United States Vanderbilt University Medical Center Nashville Tennessee
United States Ochsner Medical Center New Orleans Louisiana
United States St Luke's-Roosevelt Hospital Center New York New York
United States Rosalind Franklin University North Chicago Illinois
United States Banner University Medical Center Phoenix Arizona
United States Carilion Clinic Roanoke Virginia
United States Village Podiatry Centers Smyrna Georgia
United States UCLA Olive View Sylmar California

Sponsors (1)

Lead Sponsor Collaborator
Tissue Tech Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Complete Wound Healing Proportion of subjects with complete wound healing observed over the 16-week treatment period. Complete wound healing was defined as an initial observation of closure, followed by two confirmatory visits two weeks apart. 16-weeks
Secondary Time to Complete Wound Healing Time in number of days to complete wound closure over the 16 week treatment period, starting from enrollment to the time of the initial observation of wound closure up to 16 weeks
Secondary Percent Change in Wound Surface Area Rate of wound closure, specifically percent change in the wound surface area (cm2) at each visit from baseline for assessing the rate of wound closure in area. Only percent change in wound surface area at week 16 reported. at week 16
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT05613985 - PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers N/A
Recruiting NCT03964571 - Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients N/A
Completed NCT05616351 - Antibiotic Therapy in Infections of the Diabetic Foot Syndrome
Recruiting NCT05948592 - Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection Phase 2
Recruiting NCT04714411 - Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
Completed NCT05243810 - EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers N/A
Recruiting NCT05610865 - Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Phase 1
Recruiting NCT04450693 - Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) Phase 3
Recruiting NCT05369052 - Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI) Phase 3
Completed NCT02723539 - A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI Phase 1
Completed NCT04440839 - Implementation of Telemedicine for Patient With Lower Extremity Wounds N/A
Withdrawn NCT04289948 - Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes Phase 1/Phase 2
Completed NCT03495349 - Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
Completed NCT05564728 - Diabetes Footcare Companion App for Patients and Carers
Withdrawn NCT03354806 - Peripheral Analgesia in Painful Diabetic Neuropathy N/A
Completed NCT01594762 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Completed NCT01590758 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Active, not recruiting NCT05174806 - Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients Phase 2
Recruiting NCT04141787 - Ceftriaxone as Home IV for Staph Infections Phase 4